Reports

UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.

The BIA has coined the term ‘Deep Biotech’ to capture companies working in this biotech space. This explainer explores the disruptive impact of biology-powered Deep Biotech products and processes, their role in tackling climate change, and how the BIA is driving forward the biorevolution in the UK.

Oligonucleotide therapies are rapidly emerging as a powerful force in modern medicine poised to transform how we address a spectrum of diseases.

The UK biotech sector raised £3.5 billion in 2024, a 94% increase from the previous year, marking the highest level since 2021. Investment was concentrated in a few companies, with US investors leading the way.

This report from the BIA, alongside CPI and Cytiva, highlights the critical role the UK is playing in the field of mRNA research, outlining the opportunities the technology presents, in addition to the challenges which still have to be overcome.

Our latest UK biotech financing report documents the increase in investment the sector has seen during April-June 2024, with more money already having been raised than in the entirety of 2023.